Plain-English translation of NCT06461481 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →This trial is designed to help doctors understand the best ways to monitor patients with relapsing-remitting multiple sclerosis after they stop or reduce their disease-modifying treatment. The study uses smartwatches, blood tests, and clinical evaluations to track your health and catch any signs of disease activity early, so you and your doctor can make informed decisions together.
Many people with MS do very well on strong medications and have little or no disease activity for years. However, these powerful medications can carry risks like increased infections or cancer over the long term. This trial exists to find better ways to safely monitor patients who decide to reduce or stop their treatment, so doctors can confidently detect any problems early without relying only on traditional office visits.
You likely qualify if…
You likely don't qualify if…
You'll be asked to wear a smartwatch (provided by the study) that tracks your activity, heart rate, and sleep patterns. Depending on which study group you join, you'll have clinical visits at baseline and then every 6–24 months for up to two years, where doctors will assess your health. Some participants will also have MRI scans and blood tests to detect markers of disease activity. Throughout the study, you'll continue to work with your own doctor regarding your decision to reduce or stop treatment.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Germany